Let's increase survival for patients with drug-resistant cancers

Our Mission

Concarlo's mission is to be the world leader in p27 cancer biology and therapeutics in order to transform outcomes for cancer patients.

Our Vision

Concarlo’s vision is to transform the treatment of drug resistance by delivering on the science and technologies connected to the p27 target. We are working to create a world where there is possibility, hope and time for patients with drug-resistant cancer.

Values

Be passionate

Communicate with openness, honestly, and transparency

Give trust and hold ourselves
accountable

Have a mentoring mindset

Derive joy from our work

Drive value

Meet Our Team

We've assembled an
experienced team of
purpose-driven,
world-class leaders in
science and business

CSO

CSO

Dr. Stacy Blain

Biography

Dr. Blain is an internationally known expert in cell cycle and cancer biology, and is one of the world’s experts on p27Kip1. She has been studying cell cycle regulation for more than 25 years as an NIH funded investigator and tenured Associate Professor at the SUNY Downstate Medical Center. She founded Concarlo, capitalizing on discoveries she made and patented. She was trained at Princeton, Columbia and the Memorial Sloan-Kettering Cancer Center.

President

President

Jason Mraz

Biography

Mr. Mraz’s career has been focused in the financial markets for over 30 years since he joined JPMorgan in 1989. In 1999 he was a co-founding partner of the money management firm, Ospraie Management, where he is still an active partner today.In 2015 he teamed with Dr. Stacy Blain to found Concarlo and guides the team on all financial mattersIn 2017, he lead the development of the Ospraie AgScience team and platform, which currently invests in catalytic agricultural biotechnology.

Chief Development Officer

Chief Development Officer

Dr. Krishna Allamneni

Biography

Dr. Allamneni is a biopharma R&D expert with almost 20+ IND/IMPD submissions, 6 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates of various modalities. Forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. Impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Formerly with Turning Point, Jazz Pharmaceuticals and Genentech.

Peptide Advisor

Peptide Advisor

Dr. Dominique Bridon

Biography

Dr. Bridon is an R&D executive with extensive North American and international experience of drug development from research to proof-of-concept clinical studies (Phase II) and regulatory submission in EU and US. 20+ years of experience with peptides therapeutics including drug protein bio-conjugate development across multiple therapeutic areas to treat cancer, anti-infective, metabolic and cardiovascular diseases. He previously held various management positions at Optivia (acquired by BioIVT), Ipsen, Abbott, Enobia (acquired by Alexion) and Neuronax and served on the scientific boards of Syntaxin (acquired by Ipsen) and Biosortia. He is currently CEO of Diaccurate, a Paris-based star-up.

Nanoparticle Advisor

Nanoparticle Advisor

Sheila Matz

Biography

Ms. Matz, RPh, is a seasoned, results oriented pharmaceutical professional providing technical consulting in the areas of product formulation and process development for preclinical through Phase 4 studies. Her expertise encompasses the preparation and manufacture of a myriad of delivery systems including tablets (IR, MR and ER, orally disintegrating and thin films), capsules (hard and soft shell), spray dried and dispersed systems, liquids (solutions, micro emulsions, suspensions and nasogastric enteral systems), transdermal drug delivery systems, topicals (ointments, creams and sticks), MDI’s, DPI’s, suppositories, etc. She also has extensive experience in conducting process scale-up and validation; clinical trial material and launch supply manufacturing and packaging; technology transfers; NDA/CTD writing, etc. She has worked with Pfizer, Medivation, Boehringer Ingelheim and Key Pharmaceuticals developing proprietary NME’s as well as having worked with generic companies. Furthermore, she is named on several patents.

CMC Advisor

CMC Advisor

Jeff Millard

Biography

Jeff Millard has both academic and industrial experience in chemistry and pharmaceutical sciences covering all aspects of CMC (chemistry, manufacturing, and controls). He has been directly responsible for the research and IND authoring of more than 7 IND submissions (to both CDER and CBER), IMPDs, and several successful SBIR grant applications. His drug product experience includes pre-formulation, formulation, tech transfer and cGMP manufacturing of both solid oral dosages as well as sterile, complex parenterals including liposomes.

Chemistry Advisor

Chemistry Advisor

Dr. Robert DeVita

Biography

Dr. DeVita is an experienced medicinal chemist and drug hunter in academia, biotech and large pharmaceutical environments. He has over 30 years of drug discovery and development experience including expertise managing multi-disciplinary teams to deliver on key program objectives for complex molecular targets. Dr. DeVita started his career at Merck Research Laboratories and rose to Director of Medicinal Chemistry, where he delivered many development candidates and led drug discovery and development teams. Dr. DeVita was also VP of Chemistry at Agios Pharmaceuticals focused on oncology drug discovery. Since 2013, he founded a consulting firm which has consulted for a wide variety of clients including biotechs building translational drug discovery programs. He is also Professor in the Dept. of Pharmacological Sciences and Director of Medicinal Chemistry in the Drug Discovery Institute of Icahn School of Medicine at Mt. Sinai since 2014.

Biomedical Engineering

Biomedical Engineering

Dr. Yun Wu

Biography

Dr. Wu is an Associate Professor in the Department of Biomedical Engineering at University at Buffalo, The State University of New York (SUNY Buffalo). Her research focuses on the development of nanotherapeutics for cancer and chronic diseases and the development of in vitro diagnostic tests for cancer screening, diagnosis and prognosis. She received her Ph.D. from the Department of Chemical and Biomolecular Engineering at the Ohio State University in 2009. After completion of her degree, she received her postdoc training in the NSF Nanoscale Science and Engineering Center at the Ohio State University.

Head of Operations

Head of Operations

Sean Larkin

Biography

Sean Larkin has over a decade of experience in CFO / COO roles, spanning the startup process through corporate growth and change initiatives. His specialties include organizational management and emerging technologies. Prior to Concarlo Therapeutics, Sean was running outsourced CFO Firm LBC, LLC, working as a member of the Masotti & Masotti Digital Asset Group and as a member of MMBA, which is a blockchain education platform.

Research Assistant

Research Assistant

Maddie Whoriskey

Biography

Maddie Whoriskey is a college student at Yale University who assists with administrative tasks at Concarlo.

Meet Our Scientific
Advisors

Dr. Keren Paz

Biography

Dr. Paz is an experienced executive in the biotech and pharma space, with demonstrated leadership and expertise in precision medecine, preclinical and clinical drug development and business development. She possesses profound, applicable scientific know-how of molecular and cellular biology, biochemistry, immunology, pharmacology, CMC, regulatory and clinical trial design. Dr. Paz is currently the Chief Development Officer at Nectin Therapeutics. Prior to that she held various leadership roles in biopharma companies, including ImClone Systems, Eli Lilly, Champions Oncology, Fortress Biotech and Stelexis Therapeutics. Keren holds a PhD from The Weizmann Institute of Science in Israel and was trained at The Rockefeller University and MSKCC under the mentoring of world-renowned scientists and Nobel laureates.

Dr. Gary Schwartz

Biography

Dr. Schwartz is a board-certified medical oncologist, chief of Columbia University Medical Center’s Division of Hematology and Oncology and Deputy Director of the Herbert Irving Comprehensive Cancer Center. He is actively involved in translational and clinical research. His research studies have been supported by the National Cancer Institute, the Lustgarten Foundation for Pancreatic Cancer, the Department of Defense for Breast Cancer Research, the Byrne Foundation, and the Food and Drug Administration. He has served on the editorial boards of various scientific journals, including Associate Editor for the Journal of Clinical Oncology and Clinical Cancer Research. He is also actively involved in cooperative group activities and serves on the Board of Directors and Executive Committee of the Alliance for Clinical Trials in Oncology and is co-Chair of the Experimental Therapeutics Committee for Rare Cancers.

Dr. Andrew Koff

Biography

Andrew koff is the Head of the Laboratory of Cell Cycle Regulation
Sloan-Kettering Institute. He also serves as a professor at the Molecular Biology Program of Weill Cornell Medical College. His laboratory is interested in the mechanisms that control the decision of mammalian cells to either commit to the mitotic proliferative cycle or exit the cell cycle and differentiate, and the effect that mis-regulation of this decision has on development of a tissue and on tumor growth

Dr. Geoffrey Shapiro

Biography

Dr. Shapiro received his PhD in 1987 and his MD in 1988 from Cornell University, followed by postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he served as chief medical resident. He completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which he investigated the role of cell-cycle-related proteins in lung cancer. Dr. Shapiro’s practice is focused in the Center for Cancer Therapeutic Innovation, where he develops and leads early phase clinical trials. As Senior Vice President, Developmental Therapeutics, he also works integrally with multiple disease groups within the Institute.

Dr. Neal Rosen

Biography

Neal Rosen MD, PhD is a member of the Program in Molecular Pharmacology and the Department of Medicine at Memorial Sloan-Kettering Cancer Center where he also is the incumbent of the Enid Haupt Chair in Medical Oncology. He has pioneered the ideas that oncogene-induced negative feedback plays important roles in determining mechanisms of tumorigenesis and progression and that its relief causes adaptive resistance to targeted therapies. He has also played important roles in developing therapeutic strategies for inhibition of RAS/RAF/MEK or PI3K/mTOR signaling.

Dr. Daniel Heller

Biography

Daniel Heller is the head of the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. His laboratory develops nanotechnologies for the research, diagnosis, and treatment of cancer and allied diseases.

Meet Our Business
Advisors

Mike Miller

Biography

Mike Miller has over 40+ years of pharmaceutical and biotech industry experience. He has built/led large teams and all facets of commercialization; including General Management, Marketing, Sales Management, Market Access, Analytics, Market Research and Launch Planning. Therapeutic area experience includes Hematology Oncology, Solid Tumors (breast, lung, prostate, pancreatic), Neurology, Sleep Medicine, Reproductive Endocrinology, OBG, Pain, Urology, Cardiology, Immunology, Dermatology, and Metabolic Disease. Public and non-profit BOD experience. Consulting with private and public companies in early and late stage drug development on commercial/market assessment and market access.

Mike Harrington

Biography

Mike Harrington is a corporate executive and board member with 25 years of experience building global organizations and promoting corporate priorities in the heavily regulated life sciences industry. He has a history of increasing value across Eli Lilly’s worldwide operations through long-range vision, operational excellence and acquisitions. He provides a multidimensional perspective on corporate governance, strategic planning, enterprise risk management, and information security in regulated environments. He is also a current board member at Elanco Animal Health.

Arthur Klausner

Biography

Arthur Klausner is an experienced life science venture capitalist and company executive. He earned his M.B.A. from the Stanford University Graduate School of Business and his B.A. in Biology from Princeton University. He was previously CEO and a board member of Gem Pharmaceuticals and CEO and a board member of Jade Therapeutics. He has spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. He currently serves on the Board of Directors of Monopar Therapeutics (Nasdaq: MNPR), and on the Life Sciences Investment Review Board for the New York University Innovation Venture Fund. He currently serves as the President and CEO of Goldilocks Therapeutics, Inc.

Jay Campbell

Biography

Jay Campbell is a life sciences and finance executive with over 15 years of experience in the financial services industry, including 13 years focused on the life sciences as an investment banker working with private/public companies on strategic/M&A and financing transactions. He also has eight years of biotechnology industry experience working at private/public companies with core responsibilities of alliance management, business/corporate development, capital raising, and investor relations. Jay is currently Managing Director of the Clinical Accelerator and Venture fund at the Cancer Research Institute where he oversees the organization’s clinical trials and venture investing. He has successfully worked on 36 strategic and financing transactions and investments representing over $13.4 billion. Jay has worked at Immutep Limited, Kolltan Pharmaceuticals, Maxim Group, ABN AMRO/Royal Bank of Scotland, BIO-IB, ABN AMRO Rothschild, and Schroder & Company.

Dr. Alicia Chung

Biography

Alicia Chung is the Sr Vice President of Strategy and Business Development at Bionaut Labs, leading the company’s corporate strategy and business partnerships. Previously, she served as Head of Corporate Development at Amphivena Therapeutics, Inc, a clinical stage immunotherapy company, where she was responsible for the company’s fundraising, partnership transactions, and company operations. Prior to that, Alicia led Strategy and Business Development at Halozyme Therapeutics where she executed out-licensing of Halozyme’s drug delivery technology platform and early stage oncology assets. Alicia began her career at Roche-Genentech, where she held various positions of increasing responsibility in R&D, commercial and business development and licensing.

“If your actions inspire others to dream more, learn more, do more, and become more, you are a leader.”

—John Quincy Adams

Our Partners

Our Investors